Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SGN-CD70A · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| SGN-CD70A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SGN-CD70A | DRUG | Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks) |
Inclusion Criteria: * Metastatic renal cell carcinoma, mantle cell lymphoma, or diffuse large B-cell lymphoma including Grade 3b follicular lymphoma * Relapsed, refractory, or progressive disease following at least 2 prior systemic therapies * Confirmed positive CD70 expression on tumor tissue * Ea...
SGN-CD70A is an investigational therapy being studied in oncology for renal cell carcinoma, along with mantle cell lymphoma, diffuse large B-cell lymphoma, and grade 3 follicular lymphoma. It has been evaluated in a single Phase 1 clinical trial and is not approved for any indication.
SGN-CD70A is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor responsible for the clinical development of this oncology asset.
SGN-CD70A is in Phase 1 clinical development. It has completed one Phase 1 trial and has no active trials ongoing. The drug remains investigational and has not been approved by the FDA for any indication.
SGN-CD70A has been studied in one completed Phase 1 trial, NCT02216890, titled Safety Study of SGN-CD70A in Cancer Patients. The trial enrolled 38 participants across sites in the United States and evaluated patients with renal cell carcinoma and several lymphoma subtypes.
Yes, SGN-CD70A is a biomarker-selected therapy. Its clinical development has focused on patients whose tumors express the relevant biomarker, which is consistent with its evaluation in a targeted oncology population.